- Ultrasonography criteria for the diagnosis of early pregnancy loss have recently been redefined.
- Medical and surgical management are safe and effective, and should be influenced largely by patient preference.
- Recommendations regarding interval to next conception have recently shifted away from the traditional 3 months.
Latest Updates
Coding and Practice Management
- 2021 introduced changes to E/M billing that place greater importance on medical decision making.
- The COVID-19 Pandemic accelerated the use of Telehealth and development of associated coding strategies.
- ICD-10-CM became commonly used in the US in 2015 and ICD-11 will begin utilization in the coming years.
Medical Management of Lower Extremity Manifestations of Peripheral Artery Disease
- Randomized trials studying medical therapies to improve walking performance in patients with PAD have traditionally used treadmill walking performance as the primary outcome measure. Clinical trials of medical therapies in PAD have also measured changes in quality of life, patient perceived walking performance in daily life, the 6-minute walk, and other functional outcomes.
- Two medications are FDA-approved for treating claudication symptoms in people with PAD: pentoxifylline and cilostazol. Pentoxifylline, a methylxanthine derivative, was FDA-approved in 1984 for treating intermittent claudication symptoms due to PAD. Pentoxifylline lowers blood viscosity by increasing red blood cell deformability and flexibility. Cilostazol is a phosphodiesterase III inhibitor that was FDA-approved in 1999 for treating walking impairment due to intermittent claudication symptoms in patients with PAD.
Medical Management of Lower Extremity Manifestations of Peripheral Artery Disease
- Randomized trials studying medical therapies to improve walking performance in patients with PAD have traditionally used treadmill walking performance as the primary outcome measure. Clinical trials of medical therapies in PAD have also measured changes in quality of life, patient perceived walking performance in daily life, the 6-minute walk, and other functional outcomes.
- Two medications are FDA-approved for treating claudication symptoms in people with PAD: pentoxifylline and cilostazol. Pentoxifylline, a methylxanthine derivative, was FDA-approved in 1984 for treating intermittent claudication symptoms due to PAD. Pentoxifylline lowers blood viscosity by increasing red blood cell deformability and flexibility. Cilostazol is a phosphodiesterase III inhibitor that was FDA-approved in 1999 for treating walking impairment due to intermittent claudication symptoms in patients with PAD.
Part 2: Borderline Personality Disorder and Its Clinical Management
- Although borderline personality disorder has traditionally been perceived as difficult or impossible to treat, significant progress has been made in developing and validating treatments.
- Specialized psychotherapy remains the treatment of choice.
- Short-term or stepped care interventions may represent a more efficient treatment model.
- Common factors, such as structured therapies, may be nearly as effective as specialized treatments.
- Pharmacotherapy plays a limited role in treatment.
Medical Management of Lower Extremity Manifestations of Peripheral Artery Disease
- Randomized trials studying medical therapies to improve walking performance in patients with PAD have traditionally used treadmill walking performance as the primary outcome measure. Clinical trials of medical therapies in PAD have also measured changes in quality of life, patient perceived walking performance in daily life, the 6-minute walk, and other functional outcomes.
- Two medications are FDA-approved for treating claudication symptoms in people with PAD: pentoxifylline and cilostazol. Pentoxifylline, a methylxanthine derivative, was FDA-approved in 1984 for treating intermittent claudication symptoms due to PAD. Pentoxifylline lowers blood viscosity by increasing red blood cell deformability and flexibility. Cilostazol is a phosphodiesterase III inhibitor that was FDA-approved in 1999 for treating walking impairment due to intermittent claudication symptoms in patients with PAD.
- Use of HVPG to accurately diagnose portal hypertension
- Child-Pugh score and MELD score in risk stratification and decision-making
- Fibroelastography, multidetecter row CT scan, and capsule endoscopy as emerging modalities in detection of varices.
- Use of HVPG to accurately diagnose portal hypertension
- Child-Pugh score and MELD score in risk stratification and decision-making
- Fibroelastography, multidetecter row CT scan, and capsule endoscopy as emerging modalities in detection of varices.
